STOCK TITAN

Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Adverum Biotechnologies (Nasdaq: ADVM) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The company focuses on addressing unmet medical needs in ocular and rare diseases. A video webcast of their presentation will be available on demand starting at 10:00 am ET today and can be accessed for 30 days on their website. Adverum is advancing its gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema.

Positive
  • Participation in a significant healthcare conference may enhance visibility and investor interest.
  • Advancement of gene therapy candidate ADVM-022 showcases commitment to addressing serious ocular diseases.
Negative
  • None.

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Adverum’s video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company's website. This webcast will be available on the Adverum website for 30 days.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.


FAQ

What is Adverum Biotechnologies presenting at the Piper Sandler 32nd Annual Virtual Healthcare Conference?

Adverum Biotechnologies is presenting information regarding its gene therapy candidate, ADVM-022, targeting ocular diseases.

When will Adverum's webcast presentation be available?

The webcast presentation will be available on demand starting at 10:00 am ET on Nov. 23, 2020.

How long will Adverum's webcast be accessible?

The webcast will be accessible for 30 days on Adverum's website.

What conditions does the ADVM-022 gene therapy candidate aim to treat?

ADVM-022 is aimed at treating wet age-related macular degeneration and diabetic macular edema.

Where can I find more information about Adverum Biotechnologies?

More information about Adverum Biotechnologies can be found on their official website at www.adverum.com.

Adverum Biotechnologies, Inc.

NASDAQ:ADVM

ADVM Rankings

ADVM Latest News

ADVM Stock Data

91.63M
14.39M
16.72%
79.11%
7.03%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
REDWOOD CITY